Angiodynamics, Inc. · NASDAQ:ANGO

Angiodynamics — Q3 FY2020 Earnings Presentation

9 slides from Angiodynamics's earnings presentation, Apr 7, 2020

  1. Slide 1: AngioDynamics Third Quarter 2020 Earnings Presentation

    AngioDynamics Third Quarter 2020 Earnings PresentationApril 7, 2020

  2. Slide 2: Notice Regarding Forward-Looking Statements

    Notice Regarding Forward-Looking StatementsThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strateg

  3. Slide 3: Third Quarter FY2020 Highlights

    Third Quarter FY2020 Highlights Corporate Developments Monitoring sales, liquidity, procedural volume and third party spend in light of COVID-19. Please refer to “Risk Factors” included in Form 10-Q for the period ended February 29, 2020.Operational modifications in light of COVID-19 – Field based a

  4. Slide 4: Third Quarter FY2020 Results (unaudited)

    Third Quarter FY2020 Results (unaudited) $ in thousands (except per share data) FY2020Q3 Results FY2019Q3 Results Change FY2020YTD Results FY2019YTD Results Change Revenue Vascular Interventions and Therapies Vascular Access Oncology United States International $69,78030,55224,64214,58654,88914,891

  5. Slide 5: COVID-19 risk factor: dependence on critical facilities and supply chain

    We are dependent on the proper functioning of our critical facilities, our supply chain and distribution networks and our sales force as well as the financial stability of our customers, all of which could be negatively impacted by the coronavirus in a manner that could materially adversely affect o

  6. Slide 6: GAAP to Non-GAAP Reconciliation

    GAAP to Non-GAAP Reconciliation

  7. Slide 7: Reconciliation of GAAP to Non-GAAP Net Income and EPS

    Reconciliation of GAAP to Non-GAAP Net Income and EPS Amounts in thousands Includes costs related to merger and acquisition activities, restructurings, and unusual items, including asset impairments and write-offs, certain litigation, and other items.Deferred financing fees related to the old credit

  8. Slide 8: Reconciliation of Net Loss to Adjusted EBITDA

    Reconciliation of Net Loss to Adjusted EBITDA Amounts in thousands

  9. Slide 9: Growth through Focus Execution Accountability

    Growth through Focus Execution Accountability

AngioDynamics — Q3 FY2020 Earnings Presentation on 6ix